| dc.contributor.author | Vyas, Madhusudan | |
| dc.contributor.author | Fagan, J. | |
| dc.contributor.author | Lim, R. | |
| dc.contributor.author | Garett, N. | |
| dc.date.accessioned | 2020-12-07T22:44:38Z | |
| dc.date.available | 2020-12-07T22:44:38Z | |
| dc.date.issued | 2020-10 | |
| dc.identifier.uri | https://hdl.handle.net/10652/5028 | |
| dc.description.abstract | Objectives
Metastatic Castration resistant prostate cancer (mCRPC)
Metastatic Castration resistant prostate cancer (mCRPC) and PSMA
Various PSMA ligands and radionuclidessuitable for labelling
Lu177-PSMA and Mechanism of therapy
First reported outcome for Lu177-PSMA-617
Inclusion criteria
Exclusion criteria
Treatment protocol
Response criterion
Results: Patient Characteristics
Results: Therapy outcomes
PSA Response
Haematoxicity
Quality of Life Outcomes
Feedback from patients
Image evaluation for therapy responses
Limitations
Future plan
Conclusion
References | en_NZ |
| dc.language.iso | en | en_NZ |
| dc.relation.uri | https://www.nzsoncology.org.nz/programme | en_NZ |
| dc.rights | All rights reserved | en_NZ |
| dc.subject | cancer patients | en_NZ |
| dc.subject | prostate cancer | en_NZ |
| dc.subject | theranostics | en_NZ |
| dc.subject | radionuclide therapy | en_NZ |
| dc.subject | Lu-177 | en_NZ |
| dc.subject | Lutetium-177 | en_NZ |
| dc.subject | neuroendocrine tumours (NETs) | en_NZ |
| dc.subject | metastatic castration-resistant prostate cancer (mCRPC) | en_NZ |
| dc.subject | mCRPC | en_NZ |
| dc.subject | New Zealand | en_NZ |
| dc.title | Lutetium-177-PSMA I&T for progressing metastatic castrate-resistant prostate cancer : a single NZ centre experience | en_NZ |
| dc.type | Conference Contribution - Oral Presentation | en_NZ |
| dc.date.updated | 2020-12-02T13:30:06Z | |
| dc.rights.holder | Authors | en_NZ |
| dc.subject.marsden | 1112 Oncology and Carcinogenesis | en_NZ |
| dc.subject.marsden | 110313 Nuclear Medicine | en_NZ |
| dc.identifier.bibliographicCitation | Vyas, M., Fagan, J., Lim, R., & Garett, N. (2020, October). Lutetium-177-PSMA I&T for progressing metastatic castrate-resistant prostate cancer: A single NZ centre experience. Paper presented at the New Zealand Society for Oncology-2020, Auckland, New Zealand. | en_NZ |
| unitec.publication.title | New Zealand Society for Oncology-2020 | en_NZ |
| unitec.conference.org | New Zealand Society for Oncology | en_NZ |
| unitec.conference.location | Auckland, New Zealand | en_NZ |
| unitec.conference.sdate | 2020-10 | |
| unitec.conference.edate | 2020-10 | |
| unitec.peerreviewed | yes | en_NZ |
| dc.contributor.affiliation | Auckland University of Technology | en_NZ |
| dc.contributor.affiliation | Mercy Radiology (Auckland, N.Z.) | en_NZ |
| unitec.identifier.roms | 65178 | en_NZ |
| unitec.institution.studyarea | Health Sciences | |
